Tesamorelin is a GHRH analogue with the US reference medicine EGRIFTA. Its product-specific indication must be distinguished from general fat-loss advertising and other vials sharing the substance name.
What the research shows
The EGRIFTA WR label covers reduction of excess abdominal fat in adults with HIV-associated lipodystrophy and states it is not indicated for weight-loss management. It also distinguishes WR from SV, making formulation identity important. [1]
Distinguishing substances and products
A tesamorelin label does not establish that a vial is EGRIFTA WR or SV. A US label does not verify Thai registration of another product; match the actual product and documentation.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Is the labeled product a general weight-loss medicine?
No. EGRIFTA WR has a specific indication and is not indicated for general weight-loss management.
Should WR and SV details be mixed?
No. The labeling distinguishes the formulations.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.